NASDAQ:PATH - NuPathe Stock Price, Price Target & More

$5.20 -0.65 (-11.11 %)
(As of 04/25/2018 03:03 AM ET)
Previous Close$5.85
Today's Range$5.20 - $5.87
52-Week RangeN/A
Volume9,920 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About NuPathe (NASDAQ:PATH)

NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.

Receive PATH News and Ratings via Email

Sign-up to receive the latest news and ratings for PATH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:PATH
CUSIPN/A
Phone+1-610-2320800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

NuPathe (NASDAQ:PATH) Frequently Asked Questions

What is NuPathe's stock symbol?

NuPathe trades on the NASDAQ under the ticker symbol "PATH."

Has NuPathe been receiving favorable news coverage?

Media stories about PATH stock have been trending positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. NuPathe earned a news sentiment score of 0.35 on Accern's scale. They also assigned media headlines about the healthcare company an impact score of 48.19 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of NuPathe?

Shares of PATH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NuPathe's stock price today?

One share of PATH stock can currently be purchased for approximately $5.20.

How can I contact NuPathe?

NuPathe's mailing address is 7 Great Valley Pkwy Ste 300, MALVERN, PA 19355-1425, United States. The healthcare company can be reached via phone at +1-610-2320800.


MarketBeat Community Rating for NuPathe (PATH)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  93
MarketBeat's community ratings are surveys of what our community members think about NuPathe and other stocks. Vote "Outperform" if you believe PATH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PATH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NuPathe (NASDAQ:PATH) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/25/2016 forward)

Earnings

NuPathe (NASDAQ:PATH) Earnings History and Estimates Chart

Earnings by Quarter for NuPathe (NASDAQ:PATH)

NuPathe (NASDAQ PATH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2013Q3($0.20)($0.25)ViewListenView Earnings Details
8/8/2013Q2 2013($0.20)($0.16)ViewN/AView Earnings Details
5/14/2013Q1 2013($0.17)($0.68)ViewN/AView Earnings Details
3/26/2013Q4 2012($0.33)($1.16)ViewN/AView Earnings Details
11/12/2012Q312($0.38)($0.42)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.41)($0.42)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.41)($0.43)ViewN/AView Earnings Details
3/20/2012Q4 2011($0.50)($0.38)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.51)($0.51)ViewN/AView Earnings Details
8/15/2011Q2 2011($0.46)($0.44)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.47)($0.26)ViewN/AView Earnings Details
3/18/2011Q4 2010($0.46)($0.42)ViewN/AView Earnings Details
11/11/2010Q3 2010($0.55)($0.81)ViewN/AView Earnings Details
9/14/2010Q2 2010($17.42)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

NuPathe (NASDAQ:PATH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

NuPathe (NASDAQ PATH) Insider Trading and Institutional Ownership History

Insider Trading History for NuPathe (NASDAQ:PATH)

NuPathe (NASDAQ PATH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

NuPathe (NASDAQ PATH) News Headlines

Source:

SEC Filings

NuPathe (NASDAQ:PATH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NuPathe (NASDAQ:PATH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NuPathe (NASDAQ PATH) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.